Get access

Affibody-Functionalized Gold–Silica Nanoparticles for Raman Molecular Imaging of the Epidermal Growth Factor Receptor

Authors

  • Jesse V. Jokerst,

    1. Molecular Imaging Program at Stanford, Department of Radiology, Department of Bioengineering, Materials Science and Engineering, and Bio-X, 318 Campus Drive, Stanford, CA 94305, USA
    Search for more papers by this author
  • Zheng Miao,

    1. Molecular Imaging Program at Stanford, Department of Radiology, Department of Bioengineering, Materials Science and Engineering, and Bio-X, 318 Campus Drive, Stanford, CA 94305, USA
    Search for more papers by this author
  • Cristina Zavaleta,

    1. Molecular Imaging Program at Stanford, Department of Radiology, Department of Bioengineering, Materials Science and Engineering, and Bio-X, 318 Campus Drive, Stanford, CA 94305, USA
    Search for more papers by this author
  • Zhen Cheng,

    1. Molecular Imaging Program at Stanford, Department of Radiology, Department of Bioengineering, Materials Science and Engineering, and Bio-X, 318 Campus Drive, Stanford, CA 94305, USA
    Search for more papers by this author
  • Sanjiv S. Gambhir

    Corresponding author
    1. Molecular Imaging Program at Stanford, Department of Radiology, Department of Bioengineering, Materials Science and Engineering, and Bio-X, 318 Campus Drive, Stanford, CA 94305, USA
    • Molecular Imaging Program at Stanford, Department of Radiology, Department of Bioengineering, Materials Science and Engineering, and Bio-X, 318 Campus Drive, Stanford, CA 94305, USA.
    Search for more papers by this author

Abstract

The affibody functionalization of fluorescent surface-enhanced Raman scattering gold–silica nanoparticles as multimodal contrast agents for molecular imaging specific to epidermal growth factor receptor (EGFR) is reported. This nanoparticle bioconjugate reports EGFR-positive A431 tumors with a signal nearly 35-fold higher than EGFR-negative MDA-435S tumors. The low-level EGFR expression in adjacent healthy tissue is 7-fold lower than in the positive tumors. Validation via competitive inhibition reduces the signal by a factor of six, and independent measurement of EGFR via flow cytometry correlates at R2 = 0.92.

Ancillary